News Hub | News Direct

Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?

Sharps Technology Inc.

By David Willey, Benzinga The medical device and supply manufacturing industry is focused on the design and production of medical instruments and devices. As innovation and demand for medical devices increase, the market for this industry, which is currently worth approximately $99 billion, is very likely to grow. However, it looks like the rising tide isn’t lifting all boats equally. It has been reported that the market is rallying behind some leaders in the industry, but not others. One of the reported rising companies is Sharps Technology (NASDAQ: STSS). A specialty syringe developer and manufacturer which has a market cap of just $15 million, Sharps is a company in the space that seems to be poised for growth and is receiving positive investor sentiment. The specialty medical device company recently received a bullish sentiment stock reading from investing group InvestorsObserver. At the same time, a number of other medical device companies have seemingly received underperforming commentary or are within the feeling of market uncertainty and hesitancy, such as Becton Dickson and Co. (NYSE: BDX), Cardinal Health (NYSE: CAH), and Terumo Corporation (OTC: TRUMY). Why is it that some medical device companies such as Sharps seem to have the support of market traders, while others don’t? There may be several contributing reasons. Investment Groups are Giving Sharps Technology a Positive Outlook The forum scoreboard on Investing.com shows Sharps Technology as having a 100% bullish sentiment rating from the forum’s users. Some traders on Stocktwits have also labeled Sharps’ stock as bullish. One trader cited the reduced capital needed to manufacture, as well as the reduced liability that comes with Sharps’ products, as reasons the company is well positioned in the market. Sharps has a wholly-owned 40K sq. ft manufacturing facility in Hungary with potential capacity of up to 200 million disposable syringe units in 2024, and through its collaboration with Nephron Pharmaceuticals (private), has potential capacity of up to 50 million units of prefillable syringe systems in South Carolina. Retail investment outlet Simply Wall Street highlighted Sharps as having high growth potential, suggesting that the stock currently trades at 98% below its estimate of fair value. Meanwhile, another investment consultant praised the company for its manufacturing capacity capabilities. Manufacturing scalability potential, along with synergies through the partnership with Nephron, were mentioned as having strong potential to lead to growth in topline revenue. A couple of recent announcements from Sharps may have also contributed to this seemingly bullish market sentiment. Sharps recently announced two significant progress updates with a press release on plans to introduce new specialized prefillable syringe systems in 2023, as well as shipping the first containers of syringes from its Hungary facility for commercialization. Interested in learning more about Sharps Technology? Visit its website. This article was originally published on Benzinga here. Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and ready to use processing. The company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Adam Holdsworth- TraDigital IR adam@tradigitalir.com Company Website http://sharpstechnology.com/

March 01, 2023 09:40 AM Eastern Standard Time

Psycheceutical Bioscience, Inc (OTCPK: BWVI) Could Be Revolutionizing Psychedelic Health Care By Developing The First Ever Topical Psychedelic Cream To Treat PTSD

Psycheceutical Bioscience, Inc.

By Julian Richard, Benzinga When the average person thinks about psychedelics, it is easy to conjure up a picture of a trippy experience with hallucinogenic visions, and ‘Lucy In The Sky With Diamonds’ playing in the background. And if you aren’t familiar with the nuanced discussions that have recently arisen around the use of psychedelics for mental health treatment, you’d be right. Psychedelics are psychoactive substances that change mood, perception and cognitive processes. While psychedelics have a rich history as part of healing ceremonies, especially in indigenous communities, the popular culture connotations associated with psychedelics are firmly planted in getting high. However, in the past few years, there has been a reignited conversation about the therapeutic benefits of psychedelics – especially psilocybin and ketamine – for mental health conditions like PTSD, anxiety and depression. The vast majority of studies and products being developed deliver the drugs through oral administration or IVs. While effective, these methods of administration also have a plethora of side effects. Some of the methods of administration require professional observation, which is time-consuming for patients who have to frequent clinics for effective treatment. Side effects such as nausea, headaches, dizziness, disorientation, and confusion are common with oral and IV ketamine routes of administration. This is primarily because both forms of administration require the body to absorb through the bloodstream and digestive tract to receive positive benefits in the brain and nervous system. Additionally, if the dosage is even slightly high or the body has an adverse reaction, patients can experience what is described as a "psychedelic" effect. Ketamine, for example, is known for a specific and scary side effect nicknamed the “k-hole.” Although it's not a common side effect in clinical settings, the “k-hole” leaves users feeling disassociated from themselves and their surroundings resulting in panic or paranoia. Psycheceutical Bioscience, Inc (OTCPK: BWVI) is a biotechnology company developing a new and unique mode of administration that is revolutionizing the psychedelic mental health space. The company is developing topical administration of ketamine which allows the drug to directly target the brain and bypass the gut and liver. This process eliminates the hallucinogenic effects of psychedelic drugs and significantly reduces the toxicity and adverse effects of these compounds. The proprietary patented NeuroDirect™ non-systemic delivery technology system allows for immediate, consistent, safe, and sustained delivery of neuro-active compounds directly to the nervous system. In other words, there is no risk of a “ k-hole” side effect. The NeuroDirect™ Ketamine Topical Delivery System addresses the unmet need for rapid relief of PTSD symptoms within minutes without the requirement to be supervised in the home or spend hours in the clinic and without the side effects associated with oral or IV administration. Topical administration may be an ideal option for patients who fall into higher-risk categories like teenagers, elderly individuals, or people who have experienced previous bad trips and are weary of IV or oral administration. Currently, nothing like this exists in the medical world; Psycheceutical Bioscience is truly an innovator in the mental health care space. Psycheceutical Bioscience has successfully completed its pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA), which provided positive feedback on the development plans for NeuroDirect™ Ketamine Topical Delivery System for the treatment of post-traumatic stress disorder (PTSD). Psycheceutical Bioscience is also partnering with the Australian contract research organization iNGENū Pty Ltd. ("iNGENū") to evaluate Psycheceutical’s patented NeuroDirect™ Ketamine Topical Delivery System in Australian early-phase clinical studies. The Phase 1 study will be the first-in-human study evaluating the safety, tolerability, and pharmacokinetics of The NeuroDirect™ Ketamine Topical Delivery System in 20 healthy volunteers. The subsequent phase 2a study will be conducted on 115 individuals with PTSD and will evaluate the impact of treatment on symptoms of the condition. The phase 2 study has been designed to remove the requirement of a phase 2b trial and, if recognized by the FDA as a “pivotal” study, will allow NeuroDirect™ to proceed directly to phase 3 research. CEO of Psycheceutical, Chad Harman, shares, “We’ve developed a topical application to give people immediate relief and most patients would rather use a topical cream than needles or pills that affect the digestive system. With NeuroDirect™ ketamine, there’s no need to spend multiple hours in a clinic or being supervised at home. NeuroDirect ketamine opens up the benefits of psychedelic compounds to a much greater population, including children, the elderly, and people who don’t have the time, money, or desire to have a full-on psychedelic experience in a clinic or a retreat. Our goal is to remove the barriers and greatly increase access to the benefits of ketamine for everyone suffering from PTSD.” Psycheceutial has taken a decisive step forward in PTSD treatment by submitting an application for the first-ever ketamine topical for provisional United States Patent and Trademark Office. The provisional patent application would bring the topically-applied ketamine formulations and their associated methods in treating PTSD, to the greater global market. “PTSD can be a serious mental health disorder, with no known effective therapeutic solutions currently available. Millions of people suffer each year,” said Chad Harman, CEO of Psycheceutical. “But there is new hope. This patent application supports Psycheceutical's ongoing drug development plans for its revolutionary NeuroDirect™ topical delivery system, that we believe has the potential to provide new solutions and treatments for PTSD and other mental health conditions.” The future may look quite promising for NeuroDirect™ with their novel topical ketamine administration. With clear guidance from the FDA on the clinical trial program, IND filing is anticipated by the end of 2023. Bypassing the need to conduct a phase 2b study would accelerate the pathway to FDA approval. Collaboration with Australian contract research organization iNGENū Pty Ltd. ("iNGENū") will facilitate expedited patient access through favorable incentives offered by the Australian federal government, namely the ability to register an FDA clinical trial before opening an investigational new drug application and the rapid initiation of clinical trials. Mental health conditions like PTSD and depression can be truly debilitating and life-threatening. The promise of a topically administered drug that decreases negative side effects, cuts costs and creates a better patient experience could be a game changer for health providers and patients alike. Visit www.psycheceutical.com for more information on the company and its product candidates. This article originally appeared on Benzinga here. Psycheceutical Bioscience, Inc. is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and top minds in the psychedelic space, Psycheceutical is on a mission to commercialize its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Kaia Roman, VP Strategy and Communications kaia.roman@psycheceutical.com Company Website https://psycheceutical.com/

March 01, 2023 09:25 AM Eastern Standard Time

Right On Brands Inc. announces Chief Marketing Officer

Right On Brands, Inc.

McapMediaWire -- Right on Brands, Inc. (OTC: RTON ), a leader and innovator of HEMP DERIVED and WELLNESS products is pleased to announce today that Brock Ellison will join us as our new Chief Marketing Officer and PR officer, “Brock brings an impressive wealth of experience and knowledge to our company, having worked extensively in both digital marketing and small startups positions for over ten years say Jerry Grisaffi CEO.” In Brock's opinion, customer-centric strategies and his expertise lies in product development, digital marketing, and brand Based on his innovative and tailored thinking, companies have become more successful month-over-month after he developed his strategy. Some of those brands include AT&T, Under Armor, MAC Cosmetics, MD Anderson Cancer Center and his own digital agency, The Loyal SEO. Right On Brands Inc. and our subsidiaries truly believe the key to great marketing is understanding customers' needs and building relationships that leave a positive impact on our community. Brock is ready to show us the creativity he will bring to your favorite brand, through improving different marketing initiatives. With his leadership and knowledge, we will achieve even more by driving growth and making a positive impact on our community. On a personal note, Brock is here to help us make a real difference to improve the life of those suffering from chronic pain and illnesses. Prior to Endo Brands, he was a full-time caregiver to his mom, who passed in April 2020 from Stage 4 breast cancer. Furthermore, he has had success in digital marketing for dispensaries as he lived in Colorado from 2016 to 2018. Brock graduated from the University of Houston in 2011 with a degree in Public Relations and Marketing. “We're excited to put his skills to work for our team and the community, so we can build meaningful relationships and promote positive change”, says Grisaffi. Welcome aboard, Brock! Forward-Looking Statements This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of All such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the SEC. The forward-looking information provided herein represents the Company's estimates as of the date of this press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date after the date of this press release. If you know anyone that would like to know more about becoming an Endo Dispensary store, please contact us at: jerry@rightonbrands.com About Right on Brands: Right on Brands, Inc., (OTC: RTON) is a Dallas based, consumer goods company specializing in the brand development and distribution of hemp-based foods, beverages, smokables, oils and topical products. Right on Brands, Inc. is a developer of a broad line of hemp-based smokables, beverages, tinctures, and topical products including products infused with CBD, Delta-8, Delta-10, THCV, CBDV, and Delta-9 (below the federal limit) and the all new HHC vapes, gummies and tinctures. About ENDO Brands: ENDO Brands™, Humbly Hemp®, and ENDO Dispensary & Wellness™ Endo Franchise Group Inc, all share the same goal of providing our customers with the best products in the health and wellness space. As the field of health and wellness products expand, Right on Brands will be there with industry leading Food and Beverage and wellness Products. To learn more, please visit: https://rightonbrands.com/ www.endobrands.com www.ENDOdispensaryrowlett.com email: jerry@rightonbrands.com or mike@rightonbrands.com or call Mike Brown (214) 299-9528 ENDO Brands Corporate Store: ENDO Brands at Lakeview Plaza 6501 Dalrock Road Suite 100 Rowlett, Texas 75089 214-299-9528 AUSTIN LOCATION 12412 Limerick Avenue, Austin, Texas 78758 www.endoofaustin.com 512-621-0649 LAREDO LOCATION ENDO Laredo 2413 Jacaman Rd Laredo, Texas www.endolaredo.com 956-568-2300 HOUSTON LOCATION 3301 Louetta Rd Ste 109 Spring, Texas 77388 832-583-5383 (Website coming soon) MIAMI FLORIDA LOCATION 10850 SW 104 th St, Miami, Florida 33156 www.endo-miami.com PLANO LOCATION 601 W. Parker Road, Plano, Texas 75023 469-366-9694 NOW OPEN DALLAS LOCATION 9585 Scyene Road, Dallas. Texas NOW OPEN (Website coming soon) Contact Details Mike Brown mike@rightonbrands.com Company Website https://rightonbrands.com/

March 01, 2023 09:00 AM Eastern Standard Time

Image

Ending Pet Obesity

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/c2ScvhOzt_s There’s a weight problem in America and it isn’t just affecting humans. Would it surprise you to know that more than half of dogs and 60 percent of cats are classified as clinically overweight, but 90 percent of pet parents with an overweight pet don’t realize it. With these stats in mind, it is important for pet parents to make health and wellness a top priority. We know that eating properly and maintaining a healthy weight is key to our overall well-being. Well, the same holds true for our beloved pets. Hill’s Pet Nutrition, a global leader in science-led nutrition, is on a mission to help end pet obesity and is teaming with Dr. Vernard Hodges and Dr. Terrence Ferguson, stars of Nat Geo show: Critter Fixers: Country Vets, for its annual End Pet Obesity campaign, which was created to help pet parents understand obesity and understand the actions needed to best maintain their pet’s health by providing education, free tools and resources. Dr. Hodges and Dr. Ferguson, stars of stars of Critter Fixers: Country Vets conducted a nationwide media tour earlier this year to discuss the End Pet Obesity campaign. Topics that Dr. Hodges and Dr. Ferguson discussed included: Concerning trends they are seeing in pet health What obesity can mean for a pet Ways a pet parent can best assess if their pet is overweight Tips for weight loss and maintenance For more information, visit endpetobesity.com Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

March 01, 2023 09:00 AM Eastern Standard Time

Video

News Release

Predictive Oncology partners with Cvergenx to create new genomics-based AI radiation therapy

Predictive Oncology Inc.

Predictive Oncology CEO Raymond Vennare and Cvergenx CEO Javier Torres-Roca join Natalie Stoberman to share news of their new partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence (AI). Vennare said the objective of this collaboration will be to leverage Predictive Oncology’s drug discovery, AI and machine learning capabilities with the Cvergenx precision genomics radiation therapy platform. Contact Details Proactive US +1 347-449-0879 na-editorial@proactiveinvestors.com

March 01, 2023 07:14 AM Eastern Standard Time

Video

Poolbeg Pharma "really open" to different types of deal for POLB 001

Poolbeg Pharma PLC

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) VP of Business Development David English speaks to Proactive's Thomas Warner about the work he's doing to progress the clinical stage infectious disease pharmaceutical company's lead asset POLB 001. English says that Poolbeg is "in a good position" for partnering in general, adding that the company is "really open" to different types of deals for lead asset POLB 001. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 01, 2023 03:40 AM Eastern Standard Time

Video

Spectral MD releases final results for 2022

Spectral MD Holdings Ltd

Spectral MD Holdings Ltd (AIM:SMD) chief financial officer Nils Windler speaks to Proactive's Thomas Warner after releasing final results for 2022. Windler gives his take on the highlights from the year as well as the post-period and looks ahead to what investors can expect from the predictive analytics company in 2023. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 01, 2023 03:32 AM Eastern Standard Time

Video

Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas

Coya Therapeutics Inc.

Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary investigational biologic combination at the 2023 MDA Clinical & Scientific Conference in Dallas, Texas, to be held in-person and virtually from March 19 to March 22, 2023. The proof-of-concept open-label clinical study is the first-of-its-kind evaluating a dual-mechanism immunotherapy for the treatment of ALS. Patients in the study received investigational treatment for 12 consecutive months and were evaluated for safety and tolerability, Treg function, serum biomarkers of oxidative stress and inflammation, and clinical functioning as measured by the ALSFRS-R scale. The dual-mechanism investigational biologic combination combines low dose Interleukin-2 that is intended to enhance anti-inflammatory regulatory T cell function with a fusion protein that is intended to suppresses pro-inflammatory cell function and has been designed to be administered subcutaneously to minimize treatment burden for patients and caregivers. ALS is a disease of the parts of the nervous system that control voluntary muscle movement. In ALS, motor neurons (nerve cells that control muscle cells) are gradually lost. As these motor neurons are lost, the muscles they control become weak and then nonfunctional, thus leading to muscle weakness, disability, and eventually death. ALS is the most common form of motor neuron disease. The study was conducted at the Houston Methodist Research Institute (Houston, Texas) by Stanley Appel, M.D., Jason Thonhoff, M.D., Ph.D., and David Beers, Ph.D. Dr. Appel is chair of Coya’s Scientific Advisory Board and is former chair of the Stanley H. Appel Department of Neurology. He is the director of the Ann Kimball & John W. Johnson Center for Cellular Therapeutics, Professor of Neurology at Weill Cornell Medical College, and the Peggy and Gary Edwards Distinguished Chair for the Treatment and Research of ALS at the Houston Methodist Research Institute. Presentation details are: Title: Novel Treg-modulating Immunotherapy Targets Inflammation in ALS. Date: Tuesday, March 21, 2023, at 11:00 am CST Conference: 2023 MDA Clinical & Scientific Conference ( https://www.mdaconference.org ) This article was originally published on Benzinga here. About Coya Therapeutics, Inc. Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice Contact Details David S. Snyder David@coyatherapeutics.com Company Website https://coyatherapeutics.com/

February 28, 2023 09:00 AM Eastern Standard Time

57% of Americans Can’t Cover A $1,000 Emergency With Savings—Here’s How You Can Prepare For Unexpected Costs And Build An Emergency Fund

DentalPlans.com

By Rachael Green, Benzinga According to the 2023 Bankrate survey, just 43% of Americans would be able to cover a $1,000 emergency expense with their savings. Even fewer would be able to cover their full living expenses for at least one month if they unexpectedly lost their primary source of income. For many, inflation and unemployment are the key factors preventing them from saving as much as they would like. But having an emergency fund is an important safety net to ensure that unexpected car repairs, medical emergencies, or job losses don’t completely derail your financial future. Here’s how to figure out how much you should have in your emergency fund and some other tips for protecting yourself and your family from financial hardship. Why Should You Have An Emergency Fund? No matter how much you earn, every household is bound to face an unexpected but unavoidable expense now and then. An emergency fund acts as a safety net so that when those emergencies happen, you can pay for them without going into debt or being forced to make tough financial decisions like tapping into your 401k or downsizing your lifestyle. Typically, the costs an emergency fund is supposed to cover include: Unemployment. Even if you have unemployment insurance, it doesn’t replace your full income. An emergency fund can help cover the gap while you look for another job. Urgent medical procedures Emergency home repairs, like a new roof or foundation repairs that you can’t afford to ignore. Unexpected car repairs Sudden death or disability How Much Should You Save In Your Emergency Fund? Common wisdom states that each household should have somewhere between three to six months’ worth of expenses set aside as an emergency fund. To calculate, you can include only your absolutely essential expenses for the month like rent, utilities, and groceries. If those essentials add up to $2,000 each month, then you should save $6,000 to $12,000 in an emergency fund. If that amount seems unattainable, set a more realistic goal for yourself to start because the bottom line is any emergency savings are better than nothing. Just keep adding what you can to it. Other Ways To Prepare For Emergencies In addition to setting money aside in an emergency fund, you can also better prepare yourself for emergencies by taking steps to either prevent them from happening in the first place or lowering the cost when they do. Here are some high-impact strategies for keeping your unexpected costs down: Keep Up With Home And Car Maintenance Putting off oil changes and ignoring your check engine light can end up costing you $8,000 or more in major engine repairs later and shorten your vehicle's lifespan by as much as 50,000 miles. Putting off annual home inspections and maintenance can lead to similarly hefty repair costs down the road. If you’re living paycheck to paycheck and avoiding these routine costs because you just don’t have the cash, there’s a lot you can learn to DIY, like oil changes and filter replacements. Join a Dental Savings Plan One of the biggest unplanned expenses people face is emergency dental work. According to the National Institute of Health, 90% of U.S. adults have some untreated decay in their teeth. But with 77 million Americans living without dental insurance and millions more with limited coverage that rarely covers the cost of even one major dental procedure, many put off treatment because it’s just too costly. With root canals costing anywhere between $1,000 and $4,350 and dentures as expensive as $28,000, even those with a healthy emergency fund can end up taking a huge hit if they need urgent dental care. Fortunately, there is a way to avoid draining your emergency fund or going into debt to take care of your teeth: a dental savings plan. Dental savings plans are membership programs that allow plan members to save 10% to 60% on virtually all dental procedures ranging from routine cleanings to more expensive treatments like root canals and dentures. Those steep discounts can turn an unexpected dental emergency into a much more affordable procedure. Plan members can also get similar discounts on preventative care to lower the risk of needing that more expensive work. Many plans even offer savings on cosmetic and restorative care that may not be covered by your dental insurance. No annual limits (save every time) and no restrictions based on health conditions. To get the discounted prices, you simply have to join a plan that includes the procedure you need and is accepted by a dentist near you. Then, show your membership card to that dentist, and you’ll be billed the lower rate. With over 140,000 dentists participating in a dental savings plan nationwide, it’s easy to find one in your area. On DentalPlans.com, for example, you can search a marketplace of thousands of dental savings plans and filter by location, procedure, or dentist to find one that meets your needs. You can also find plans that offer discounts on vision care and prescription medications to cut costs further. Consider Life Insurance And Disability Insurance In the case of sudden death or disability, even a 3-6-month emergency fund may not be enough to cover the lost income—especially after you factor in funeral expenses or, in the case of disability, the cost of medical care. A life insurance or disability insurance policy can protect your family from financial hardship in those worst-case scenarios. Visit DentalPlans.com for more information. Discount Health Program consumer & provider surveys indicate average savings of 50%. Savings may vary by provider, location, and plan. This article was originally published on Benzinga here. DentalPlans.com, founded in 1999, is a leading online marketplace for dental savings plans in the U.S., helping more than a million people to affordably access quality healthcare services. Our mission is to empower consumers with the tools, information, and services that they need to live happier, healthier lives. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details Matthew Wong matthew.wong@wpromote.com Company Website https://www.dentalplans.com/

February 28, 2023 09:00 AM Eastern Standard Time

Healthcare

Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?

Psycheceutical Bioscience, Inc (OTCPK: BWVI) Could Be Revolutionizing Psychedelic Health Care By Developing The First Ever Topical Psychedelic Cream To Treat PTSD

Right On Brands Inc. announces Chief Marketing Officer

Ending Pet Obesity

Predictive Oncology partners with Cvergenx to create new genomics-based AI radiation therapy

Poolbeg Pharma "really open" to different types of deal for POLB 001

Spectral MD releases final results for 2022

Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas

57% of Americans Can’t Cover A $1,000 Emergency With Savings—Here’s How You Can Prepare For Unexpected Costs And Build An Emergency Fund